Li Fei, Ren Yi, Wang Zhandong
Department of Pathology, Xuzhou Cancer Hospital, Xuzhou 221000, PR China.
Department of Breast Surgery, Xuzhou Cancer Hospital, Xuzhou 221000, PR China.
J Cancer Res Ther. 2018 Jan;14(1):150-154. doi: 10.4103/jcrt.JCRT_602_17.
To evaluate the expression of programmed death 1 ligand 1 (PD-L1) in the cancer tissues and tumor-adjacent normal tissues of patients with invasive ductal carcinoma of the breast and to analyze the relationship between the expression of PD-L1 and the clinicopathological features of patients.
This study included 112 cases of patients with invasive ductal carcinoma of breast who received surgical treatment from March 2012 to February 2016 in Xuzhou Cancer Hospital. The clinical materials of included patients were retrospectively analyzed. The immunohistochemical assay and real-time polymerase chain reaction (PCR) assay were applied to examine the expression of mRNA and protein of PD-L1 in breast cancer specimens of 112 cases and paired tumor-adjacent tissue specimens of 57 cases. The relationship between PD-L1 protein expression and clinicopathological features of patients was analyzed.
PD-L1 protein was mainly expressed in the cytoplasm. The positive rate of PD-L1 expression in invasive ductal carcinoma was 19.6% (22/112), and the positive rate of PD-L1 expression of tumor-adjacent normal tissues was 3.5% (2/57), indicating that the positive rate of PD-L1 expression of cancerous tissues was significantly higher than that of in tumor-adjacent normal tissues (P < 0.05); the positive expression of PD-L1 was not related with the patients' age, menopause history, family history of breast cancer, tumor size, and location of the tumor (P > 0.05) while it was related with lymph node metastasis, the clinic staging, and histopathological grading (P < 0.05). Real-time PCR was applied to detect the mRNA expression of PD-L1 in breast-invasive ductal carcinoma with the mean ΔCt value of 7.79 ± 2.25. However, the mRNA expression of PD-L1 in normal tumor-adjacent tissues was of low expression with the mean ΔCt value of 12.37 ± 3.33. The difference was statistically significant (P< 0.05).
The expression of PD-L1 in breast-invasive ductal carcinoma was significantly increased, and it was related to histological grading, clinical staging, and lymph node metastasis of breast cancer. PD-L1 may be a significant marker for the prognosis of breast cancer patients.
评估程序性死亡1配体1(PD-L1)在乳腺浸润性导管癌患者癌组织及癌旁正常组织中的表达情况,并分析PD-L1表达与患者临床病理特征之间的关系。
本研究纳入2012年3月至2016年2月在徐州市肿瘤医院接受手术治疗的112例乳腺浸润性导管癌患者。对纳入患者的临床资料进行回顾性分析。采用免疫组织化学法和实时聚合酶链反应(PCR)法检测112例乳腺癌标本及57例配对癌旁组织标本中PD-L1的mRNA和蛋白表达情况。分析PD-L1蛋白表达与患者临床病理特征之间的关系。
PD-L1蛋白主要表达于细胞质中。乳腺浸润性导管癌中PD-L1表达阳性率为19.6%(22/112),癌旁正常组织中PD-L1表达阳性率为3.5%(2/57),癌组织中PD-L1表达阳性率显著高于癌旁正常组织(P<0.05);PD-L1阳性表达与患者年龄、绝经史、乳腺癌家族史、肿瘤大小及肿瘤位置无关(P>0.05),而与淋巴结转移、临床分期及组织病理学分级有关(P<0.05)。采用实时PCR检测乳腺浸润性导管癌中PD-L1的mRNA表达,平均ΔCt值为7.79±2.25。而癌旁正常组织中PD-L1的mRNA表达呈低表达,平均ΔCt值为12.37±3.33。差异具有统计学意义(P<0.05)。
乳腺浸润性导管癌中PD-L1表达显著升高,且与乳腺癌的组织学分级、临床分期及淋巴结转移有关。PD-L1可能是乳腺癌患者预后的重要标志物。